Para ordenar a la Comisión de Salud de la Cámara de Representantes del Gobierno de Puerto Rico, a realizar una investigación exhaustiva sobre la eliminación y/o exclusión de medicamentos utilizados para el tratamiento de obesidad y condiciones asociadas —incluyendo, pero sin limitarse, a Zepbound— del formulario del Plan Vital administrado por la Administración de Seguros de Salud de Puerto Rico (ASES); evaluar el proceso utilizado para dicha determinación; el impacto clínico, físico y mental en los pacientes; la participación de profesionales de la salud en dicha decisión; y para otros fines relacionados.

2025-2028 Session

Puerto Rico orders investigation into removal of obesity drugs like Zepbound from government health plan formulary, examining decision process and patient impact.

Remitido a Comisión de Calendarios y Reglas Especiales de Debate de la Cámara

Legislative bill overview

Bill RC 536 orders Puerto Rico's Chamber of Representatives Health Commission to conduct a comprehensive investigation into why obesity treatment medications—particularly Zepbound—were removed from or excluded from the Vital Plan formulary administered by Puerto Rico's Health Insurance Administration (ASES). The investigation must evaluate the decision-making process, clinical and mental health impacts on patients, and the involvement of healthcare professionals in this determination.

Why is this important

Obesity medications represent a growing treatment option for a significant public health concern, and their inclusion or exclusion from government health plans directly affects patient access and financial burden. The investigation addresses transparency in pharmaceutical coverage decisions and whether medical professionals were adequately consulted, which impacts how future drug coverage decisions are made across Puerto Rico's public health system.

Potential points of contention

Cost vs. Access: Obesity medications are expensive; ASES may have excluded them for budgetary reasons, creating tension between fiscal responsibility and patient access to treatment options

Clinical Evidence Standards: Disagreement may exist over whether these medications meet clinical efficacy thresholds for formulary inclusion or whether they're considered elective/cosmetic rather than medically necessary

Healthcare Professional Involvement: The investigation assumes professionals should have been consulted; findings may reveal either insufficient input from physicians or that medical recommendations were deprioritized for financial/administrative reasons